Post Intelligence – company profile: Eli Lilly and Company
Some of the Groups major drugs will all lose patent protection between 2011 and 2013.
Four of these represented more than 40% of Group sales in FY12. However, the strength of the Group’s late stage pipeline should help it bring new products to market.
This company report has been
Only users who have a paid subscription or are part of a corporate subscription are able to print or copy content.
To access these options, along with all other subscription benefits, please contact info@postonline.co.uk or view our subscription options here: http://subscriptions.postonline.co.uk/subscribe
You are currently unable to print this content. Please contact info@postonline.co.uk to find out more.
You are currently unable to copy this content. Please contact info@postonline.co.uk to find out more.
Copyright Infopro Digital Limited. All rights reserved.
You may share this content using our article tools. Printing this content is for the sole use of the Authorised User (named subscriber), as outlined in our terms and conditions - https://www.infopro-insight.com/terms-conditions/insight-subscriptions/
If you would like to purchase additional rights please email info@postonline.co.uk
Copyright Infopro Digital Limited. All rights reserved.
You may share this content using our article tools. Copying this content is for the sole use of the Authorised User (named subscriber), as outlined in our terms and conditions - https://www.infopro-insight.com/terms-conditions/insight-subscriptions/
If you would like to purchase additional rights please email info@postonline.co.uk
Most read
- British Insurance Awards 2024 shortlist revealed
- British Insurance Technology Awards shortlist 2024 announced
- ‘Common sense prevails’ as Supreme Court rejects insurer mixed injury appeals